Physician profile
Jonathan M Gloth
NPI 1932361110
$2,426.88
in general payments reported to CMS, 2019-2025
20 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $191 · 2021: $98.30 · 2022: $478 · 2023: $534 · 2024: $548 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $663.98 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $421.86 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $183.52 | 2022-2025 | Eylea |
| Novartis Pharmaceuticals Corporation | $171.47 | 2019-2023 | |
| Eyepoint US, INC. | $130.83 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $128.34 | 2023-2025 | Xipere, Vyzulta, Xiidra |
| Glaukos Corporation | $123.89 | 2022 | |
| Sun Pharmaceutical Industries INC. | $108.51 | 2021-2024 | Cequa |
| Alcon Vision LLC | $88.52 | 2023-2025 | Total30, Rocklatan, Tryptyr |
| Biotissue Holdings INC. | $69.35 | 2022-2024 | |
| Dompe US, INC. | $69.05 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $54.02 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $52.57 | 2022-2024 | Vabysmo |
| Oyster Point Pharma, INC. | $35.65 | 2024 | Tyrvaya, Ryzumvi |
| Apellis Pharmaceuticals, INC. | $35.38 | 2023-2024 | Syfovre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.21 | 2019-2021 | |
| Halozyme INC | $19.23 | 2022 | |
| Harrow Eye, LLC | $16.35 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $14.07 | 2019 | |
| Boston Scientific Corporation | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gloth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.